Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

by Kim, Dong Joon , Canducci, Filippo , Peng, Cheng-Yuan , Chughlay, Farouk , Huang, Yan , Hou, Jinlin , Upmanyu, Ruchi , Gane, Edward , Hua, Rui , Wat, Cynthia , Glavini, Katerina , Zhang, Wenhong , Das, Sudip , Patil, Avinash , Kakrana, Priyanka , Kao, Jia-Horng , Avihingsanon, Anchalee , Surujbally, Bernadette , Liang, Xieer , Chen, Ethan , Yang, Sheng-Shun , Guerreiro, Nelson , Triyatni, Miriam , Xie, Qing , Su, Wei-Wen , Chuang, Wan-Long , Leerapun, Apinya , Bo, Qingyan , Morano Amado, Luis Enrique , Catanese, Maria Teresa , Kazma, Rémi , Asselah, Tarik , Yuen, Man-Fung , Cheng, Cong , Pavlovic, Vedran , Tang, Hong

in Adult / Adverse events / Alanine transaminase / Antigens / Antiviral Agents - administration & dosage / Antiviral Agents - adverse effects / Chronic infection / Clinical significance / Drug dosages / Drug Therapy, Combination - adverse effects / Drug Therapy, Combination - methods / Female / Gastroenterology / Gastroenterology General / Genetics / Genetics General / Global Health / Hepatitis B / Hepatitis B surface antigen / Hepatitis B Surface Antigens - blood / Hepatitis B virus - drug effects / Hepatitis B virus - genetics / Hepatitis B virus - immunology / Hepatitis B, Chronic - blood / Hepatitis B, Chronic - drug therapy / Hepatitis B, Chronic - immunology / Humans / Immunomodulating Agents - administration & dosage / Immunomodulating Agents - adverse effects / Immunomodulation / Immunomodulators / Infections / Infectious Disease / Infectious Disease General / Interferon-alpha - administration & dosage / Interferon-alpha - adverse effects / Liver cancer / Liver cirrhosis / Liver Disease / Male / Middle Aged / Nucleoside analogs / Nucleosides - administration & dosage / Nucleosides - adverse effects / Nucleosides - analogs & derivatives / Nucleotide analogs / Polyethylene Glycols - adverse effects / Polyethylene Glycols - therapeutic use / Recombinant Proteins - administration & dosage / Recombinant Proteins - adverse effects / RNA Therapeutics / RNA viruses / RNA, Small Interfering - administration & dosage / RNA, Small Interfering - adverse effects / Seroconversion / siRNA / Treatment Outcome / Viral Infections / α-Interferon

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

2024

Confirm

Do you wish to request the book?

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

Kim, Dong Joon,

Canducci, Filippo,

Peng, Cheng-Yuan,

Chughlay, Farouk,

Huang, Yan,

Hou, Jinlin,

Upmanyu, Ruchi,

Gane, Edward,

Hua, Rui,

Wat, Cynthia,

Glavini, Katerina,

Zhang, Wenhong,

Das, Sudip,

Patil, Avinash,

Kakrana, Priyanka,

Kao, Jia-Horng,

Avihingsanon, Anchalee,

Surujbally, Bernadette,

Liang, Xieer,

Chen, Ethan,

Yang, Sheng-Shun,

Guerreiro, Nelson,

Triyatni, Miriam,

Xie, Qing,

Su, Wei-Wen,

Chuang, Wan-Long,

Leerapun, Apinya,

Bo, Qingyan,

Morano Amado, Luis Enrique,

Catanese, Maria Teresa,

Kazma, Rémi,

Asselah, Tarik,

Yuen, Man-Fung,

Cheng, Cong,

Pavlovic, Vedran,

Tang, Hong

2024

Overview

In a phase 2 trial involving participants taking a nucleoside or nucleotide analogue, 23% of those assigned to receive xalnesiran plus pegylated interferon alfa-2a had HBsAg loss at 24 weeks after the end of treatment.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Adverse events

/ Alanine transaminase

/ Antigens

/ Antiviral Agents - administration & dosage

/ Antiviral Agents - adverse effects

/ Chronic infection